NEW YORK, December 24, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Novartis AG (ADR) (NYSE: NVS), Teva Pharmaceutical Industries Ltd. (ADR) (NYSE: TEVA), Universal Health Services Inc. (NYSE: UHS), and Becton, Dickinson and Co. (NYSE: BDX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Pfizer Inc. Research Report
On December 19, 2013, Pfizer Inc. (Pfizer), along with Bristol-Myers Squibb Company (Bristol-Myers Squibb), announced that the US Food and Drug Administration (FDA) has accepted for review a Supplemental New Drug Application (sNDA) for ELIQUIS (apixaban) for the treatment of vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE. According to Pfizer, the sNDA submission is supported by results from two Phase 3 trials, AMPLIFY and AMPLIFY-EXT, both originally published in The New England Journal of Medicine on June 30, 2013, and December 8, 2012, respectively. Pfizer said that the Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is August 25, 2014. Pfizer added that the European Medicines Agency accepted for review an application for ELIQUIS for the treatment of DVT and PE, and prevention of recurrent DVT and PE in November 2013. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Novartis AG (ADR) Research Report
On December 19, 2013, Sandoz, the generic pharmaceuticals division of Novartis AG (ADR) (Novartis), announced that it has initiated a Phase III clinical trial with its biosimilar version of adalimumab (AbbVie's HUMIRA), the leading treatment of several autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn's disease. According to Sandoz, the aim of the study is to demonstrate equivalent efficacy, similarity, and immunogenicity of the Sandoz product versus HUMIRA in patients with moderate to severe plaque-type psoriasis. Mark McCamish, M.D., Ph.D., and Head of Global Biopharmaceutical & Oncology Injectables Development at Sandoz, said, "This latest advancement in our pipeline represents our unwavering commitment to expanding patient access to biologics - particularly in disease areas where there is a significant need for more treatment choices." McCamish added, "We look forward to bringing a high-quality and affordable biosimilar version of adalimumab to individuals around the world living with psoriasis and other debilitating autoimmune diseases such as rheumatoid arthritis." The Full Research Report on Novartis AG (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Teva Pharmaceutical Industries Ltd. (ADR) Research Report
On December 19, 2013, Teva Pharmaceutical Industries Ltd. (ADR) (Teva) announced that the Company will release its Q4 2013 financial results on February 6, 2014 at 7:00 a.m. ET. The Company added that it will host a conference call and live webcast on the same day, at 8:00 a.m. ET, to discuss its Q4 2013 results and overall business environment, followed by a Q&A session. The Full Research Report on Teva Pharmaceutical Industries Ltd. (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Universal Health Services Inc. Research Report
On December 19, 2013, Universal Health Services Inc.'s (Universal Health Services) stock declined 1.88%, ending the day at $79.02. Over the previous three trading sessions, shares of United Health Services declined 2.35%, compared to the S&P 500 which gained 1.29% during the same trading period. The Full Research Report on Universal Health Services Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Becton, Dickinson and Co. Research Report
On December 19, 2013, Becton, Dickinson and Co.'s (BD) stock declined 0.49%, ending the day at $108.02. Over the previous three trading sessions, shares of BD gained 2.02%, compared to the S&P 500 which gained 1.29% during the same trading period. The Full Research Report on Becton, Dickinson and Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner